SCH-94.03
- Generic Name
- SCH-94.03
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis Immediately Following a Relapse
Phase 1
Completed
- Conditions
- Multiple Sclerosis, Acute Relapsing
- Interventions
- Drug: Placebo
- First Posted Date
- 2015-03-25
- Last Posted Date
- 2018-08-22
- Lead Sponsor
- Acorda Therapeutics
- Target Recruit Count
- 27
- Registration Number
- NCT02398461
- Locations
- 🇺🇸
Acorda Site #16, Centennial, Colorado, United States
🇺🇸Acorda Site #22, Chicago, Illinois, United States
🇺🇸Acorda Site #19, Teaneck, New Jersey, United States
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
- First Posted Date
- 2013-03-04
- Last Posted Date
- 2015-02-27
- Lead Sponsor
- Acorda Therapeutics
- Target Recruit Count
- 72
- Registration Number
- NCT01803867
- Locations
- 🇺🇸
Acorda Investigational Site, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath